NCT00026143View on ClinicalTrials.gov

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

July 31, 2004

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
BIOLOGICAL

recombinant interleukin-12

Given IV

BIOLOGICAL

recombinant interferon alfa

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00026143 - Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter